Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 547

1.

Current status and progress of prepandemic and pandemic influenza vaccine development.

Leroux-Roels I, Leroux-Roels G.

Expert Rev Vaccines. 2009 Apr;8(4):401-23. doi: 10.1586/erv.09.15. Review.

PMID:
19348557
4.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
5.

Progress with human H5N1 vaccines: a perspective from industry.

Palache B, Krause R.

Expert Rev Vaccines. 2009 Apr;8(4):391-400. doi: 10.1586/erv.09.16. Review.

PMID:
19348556
6.

Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.

Kreijtz JH, Osterhaus AD, Rimmelzwaan GF.

Hum Vaccin. 2009 Mar;5(3):126-35. Epub 2009 Mar 15. Review.

PMID:
18948744
7.

[Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].

Loulergue P, Launay O.

Med Sci (Paris). 2009 Aug-Sep;25(8-9):719-25. doi: 10.1051/medsci/2009258-9719. Review. French.

8.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
9.

Pandemic H5N1 influenza vaccine development: an update.

El Sahly HM, Keitel WA.

Expert Rev Vaccines. 2008 Mar;7(2):241-7. doi: 10.1586/14760584.7.2.241. Review.

PMID:
18324892
10.

Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.

Hasegawa H, Ichinohe T, Tamura S, Kurata T.

Expert Rev Vaccines. 2007 Apr;6(2):193-201. Review.

PMID:
17408369
11.

Emulsion-based adjuvants for influenza vaccines.

Vogel FR, Caillet C, Kusters IC, Haensler J.

Expert Rev Vaccines. 2009 Apr;8(4):483-92. doi: 10.1586/erv.09.5. Review.

PMID:
19348563
12.

Influenza A (H5N1) pandemic prototype vaccine Fluval.

Vajo Z.

Expert Rev Vaccines. 2009 May;8(5):619-24. doi: 10.1586/erv.09.25. Review.

PMID:
19397418
13.

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.

Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.

Pediatr Infect Dis J. 2010 Jun;29(6):e35-46. doi: 10.1097/INF.0b013e3181daf921.

PMID:
20375709
14.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

15.

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.

Hehme N, Engelmann H, Künzel W, Neumeier E, Sänger R.

Med Microbiol Immunol. 2002 Dec;191(3-4):203-8. Epub 2002 Oct 19.

PMID:
12458361
16.

H5N1 vaccines in humans.

Baz M, Luke CJ, Cheng X, Jin H, Subbarao K.

Virus Res. 2013 Dec 5;178(1):78-98. doi: 10.1016/j.virusres.2013.05.006. Epub 2013 May 28. Review.

17.

Development of vaccines against influenza A virus (H5N1).

Li WC, Huang YC.

Chang Gung Med J. 2007 Jul-Aug;30(4):294-304. Review.

18.

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

Keitel WA, Atmar RL.

Curr Opin Pharmacol. 2007 Oct;7(5):484-90. Epub 2007 Jul 17. Review.

PMID:
17644429
19.

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

Howard MK, Kistner O, Barrett PN.

Biol Chem. 2008 May;389(5):569-77.

PMID:
18953724
20.

Developing vaccines against pandemic influenza.

Wood JM.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1953-60.

Supplemental Content

Support Center